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ORIGINAL ARTICLE

Increased perfusion and angiogenesis in a hindlimb
ischemia model with plasmid FGF-2 delivered by
noninvasive electroporation
B Ferraro1, YL Cruz1, M Baldwin2, D Coppola3 and R Heller1,4
1
Department of Molecular Medicine, University of South Florida, Tampa, FL, USA; 2Division of Comparative Medicine, University of
South Florida, Tampa, FL, USA; 3Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA and 4Frank Reidy
Research Center for Bioelectrics, Old Dominion University, Norfolk, VA, USA

Gene therapy approaches delivering fibroblast growth factor2 (FGF-2) have shown promise as a potential treatment for
increasing blood flow to ischemic limbs. Currently, effective
noninvasive techniques to deliver plasmids encoding genes
of therapeutic interest, such as FGF-2, are limited. We
sought to determine if intradermal injection of plasmid DNA
encoding FGF-2 (pFGF) followed by noninvasive cutaneous
electroporation (pFGFE+) could increase blood flow and
angiogenesis in a rat model of hindlimb ischemia. pFGFE+ or
control treatments were administered on postoperative day
0. Compared to injection of pFGF alone (pFGFE), delivery
of pFGFE+ significantly increased FGF-2 expression for
10 days. Further, the increase in FGF-2 expression with

pFGFE+ was sufficient to significantly increase ischemic limb
blood flow, measured by laser Doppler perfusion imaging,
beginning on postoperative day 3. Ischemic limb blood flow
in the pFGFE+ treatment group remained significantly higher
than all control groups through the end point of the study,
postoperative day 14. Immunohistochemical staining of
gastrocnemius cross sections determined there was a twofold
increase in capillary density in the pFGFE+ treatment group.
Our results suggest that pFGFE+ is a potential noninvasive,
nonviral therapeutic approach to increase perfusion and
angiogenesis for the treatment of limb ischemia.
Gene Therapy (2010) 17, 763–769; doi:10.1038/gt.2010.43;
published online 15 April 2010
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Introduction
Peripheral artery disease (PAD), resulting from atherosclerosis, is one of the leading causes of morbidity and
mortality in the western world.1 The primary pathophysiology of PAD is reduction of blood flow to the
lower extremities that commonly results in one of two
clinical presentations, intermittent claudication (IC) or
critical limb ischemia (CLI). IC is manifested by insufficient blood flow during exercise. The more severe
manifestation, CLI, results from insufficient blood flow
to the limb even when the effected limb is at rest. Current
treatment options for PAD include risk factor reduction,
physical therapy and training, and pharmacological
treatment of the underlying atherosclerosis. Also, in
patients with severe IC or CLI, interventional (catheterbased) or open surgical procedures may be used to
revascularize the ischemic limb. However, direct
revascularization is often impossible due to the anatomic
extent of PAD and is also limited by associated comorbidities, such as diabetes, coronary artery disease or
Correspondence: Dr R Heller, Frank Reidy Research Center for
Bioelectrics, School of Medical Laboratory and Radiation Sciences,
Old Dominion University, 830 Southampton Avenue Suite 5100,
Norfolk, VA 23510, USA.
E-mail: rheller@odu.edu
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stroke, requiring a majority of patients to undergo limb
amputation.2–5 Currently, an effective pharmacological
treatment to increase blood flow to ischemic limbs is not
available.6 The lack of an effective pharmacological
treatment and the limits of interventional and surgical
procedures have spurred an intense investigation of
alternative approaches, such as therapeutic angiogenesis,
for the treatment of PAD.
Angiogenesis has a major role in both health and
disease. The formation of new blood vessels occurs
during normal physiological processes, such as embryonic development and wound healing.7 Insufficient
neovascularization is characteristic of several diseases
including ischemic heart and limb diseases, neurodegeneration and osteoporosis.8 The initiation and
progression of angiogenesis is mediated through the
production of growth factors and cytokines in response
to disease or injury. Therapeutic approaches delivering
angiogenic growth factors, such as members of the
vascular endothelial growth factor and fibroblast growth
factor (FGF) families, are emerging as promising treatment options for IC and CLI in patients when direct
revascularization is not possible.9 FGFs have an integral
role in angiogenesis by modulating multiple steps including degradation of the extracellular matrix and promotion of vascular endothelial cell proliferation, migration
and morphogenesis.10 There are currently greater than 20
known FGFs that share approximately 30–70% homology
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in their amino-acid sequences. Of the FGF family
members, FGF-1 and FGF-2 have been the most intensely
studied and most frequently used in emerging therapeutic angiogenesis approaches.
The overall aim of this study was to elucidate
a noninvasive therapeutic approach for delivering
FGF-2 as a potential treatment for IC and CLI. In
previous studies, intramuscular injection of plasmid
FGF-2,12 alone or followed by intramuscular electroporation (EP),13,14 increased angiogenesis and blood flow to
ischemic limbs. In this study, we show that delivery of a
plasmid encoding FGF-2 (pFGF) to the skin by intradermal injection and noninvasive EP (pFGFE+) significantly increases FGF-2 expression compared to injection
of the plasmid without EP (pFGFE). The increase in
FGF-2 expression with pFGFE+ was sufficient to significantly increase blood flow and angiogenesis in a rat
model of limb ischemia. The results presented here
suggest that pFGFE+ is a novel potential noninvasive
therapeutic angiogenesis approach for the treatment of
PAD-related limb ischemia.

Results
FGF-2 expression kinetics
After determining pFGF transfection increased FGF-2
protein expression in vitro (data not shown), we then
determined if pFGFE+ could increase FGF-2 protein
expression in vivo (Figure 1). At the time points indicated
in Figure 1, skin from the treated areas was excised and
assayed for FGF-2 expression by enzyme-linked immunosorbent assay. For 10 days after treatment, pFGFE+
significantly increased FGF-2 protein levels, compared to
pFGFE, (Po0.05) before decreasing to background
levels at days 14 and 17. The application of an electric
field to tissues alone can transiently induce expression of
some genes, including angiogenic growth factors,15,16 but

Figure 1 FGF-2 expression kinetics. At the indicated time points,
skin samples were harvested from the delivery site and assayed for
FGF-2 protein expression by enzyme-linked immunosorbent assay
(ELISA). To determine FGF-2 expression resulting from pFGFE+
and pFGFE, the average FGF-2 expression in untreated skin (n ¼ 4,
1416±326 total pg per sample) was subtracted from the total pg per
sample for each treatment site. Day 2, n ¼ 10; days 4, 7 and 10, n ¼ 6
and days 14 and 17, n ¼ 8 per group per time point.
pFGFE+ ¼ 300 V cm1, 150 ms. **Po0.01, *Po0.05. pFGFE, intradermal injection of plasmid FGF-2; pFGFE+, intradermal injection
of plasmid FGF-2 followed by electroporation.
Gene Therapy

injection of the vector backbone, lacking the FGF-2 cDNA
insert, followed by EP (pVAXE+) resulted in similar
levels of FGF-2 expression as untreated controls (PE)
(n ¼ 4, 1416±326 total pg per sample).

Plasmid FGF-2 with EP increases blood flow in the
ischemic hindlimb
We next evaluated if pFGFE+ treatment could increase
blood flow in a rat model of hindlimb ischemia.
Immediately postoperatively (day 0) pFGFE+ or control
treatments were administered at two sites on the medial
aspect of the ischemic limb. A laser Doppler perfusion
imager was used to measure perfusion in the distal area
of both the ischemic and nonischemic limbs preoperatively (baseline), postoperatively but before treatment
(day 0) and on postoperative days (PODs) 1, 3, 7 and 14
(Figure 2a). Immediately postoperatively, blood flow
decreased to approximately 40% of baseline indicating
the hindlimb was effectively rendered ischemic. In
Figure 2b blood flow is reported for each treatment group
as the ratio of blood flow in the ischemic hindlimb to
the nonischemic hindlimb (I/NI) (Figure 2b, top panel)
and as a percent of the perfusion recorded at baseline
(Figure 2b, bottom panel). There was a significant
difference in limb blood flow beginning on POD 3
between all treatment groups for I/NI (Po0.02) and as
a percentage of baseline levels (Po0.001). Also on POD 3,
blood flow in the pFGFE+ treatment group was significantly greater than all of the control groups (Po0.05).
Blood flow in the ischemic limb continued to be higher
in the pFGFE+ treatment group, compared to control
treatment groups, at all subsequent time points in the
study (Po0.05, all time points for percent of baseline
blood flow and I/NI). The pFGFE treatment group
showed a slight, but not significant, increase in blood flow
compared to the pVAXE+ and PE treatment groups on
PODs 7 and 14.
Plasmid FGF-2 with EP increases angiogenesis in the
ischemic hindlimb
Next, we determined if the increase in limb perfusion in
the pFGFE+ treatment group resulted from an increase in
angiogenesis. In rodent models of hindlimb ischemia, as
well as in patients with PAD, angiogenesis typically
occurs in the gastrocnemius muscle, or distal to the
arterial occlusion.17 Thus, on POD 14 samples were
harvested from the gastrocnemius muscle of the ischemic
limb and capillary density visualized by immunohistochemical staining for the endothelial cell marker factorVIII-associated antigen. Representative fields (  400)
from each of the four treatment groups are shown in
Figure 3a. In Figure 3b, the average number of vessels in
five randomly selected high-power fields (  400) for five
animals in each treatment group is reported. There was
an approximately twofold increase in the number of
capillaries in the pFGFE+ treatment group, compared to
all control groups (Po0.001), indicating the increase in
blood flow to the ischemic limb with pFGFE+ was in fact
due to an increase in angiogenesis.

Discussion
Direct injection of naked plasmid DNA has been
intensively investigated as a gene delivery approach for
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Figure 2 Effect of pFGFE+ on ischemic limb blood flow. (a)
Representative laser Doppler perfusion images for the pFGFE+ and
pFGFE treatment groups from baseline to day 14 postoperatively.
The white box indicates the approximate area where blood flow was
assessed. The arrows indicate the absence of perfusion in the area of
the femoral artery after the operation to induce hindlimb ischemia.
(b) Quantification of blood flow as determined by laser Doppler
perfusion imaging. (Top panel) Ratio of blood flow in the ischemic
limb to the nonischemic limb (I/NI). (Bottom panel) Postoperative
blood flow as a percentage of baseline line blood flow. n ¼ 6 per
group per time point. *Po0.05 compared to all controls. pFGFE+,
intradermal injection of plasmid FGF-2 followed by electroporation;
pFGFE, intradermal injection of plasmid FGF-2; pVAXE+, intradermal injection of vector backbone followed by electroporation;
PE, no treatment.

the treatment of a variety of diseases. One drawback to
this approach is inefficient uptake of the plasmid by cells
resulting in low levels of gene expression.18 In vivo EP

Figure 3 Effect of pFGFE+ on neovascularization. (a) Representative cross sections (  400) of factor VIII-associated antigen
immunohistological staining of cross sections excised from the
gastrocnemius on POD 14. Arrows indicate examples of stained
vessels. (b) Quantification of capillary density. The average number
of capillaries in five fields, for five animals in each treatment group.
*Po0.01 compared to all controls. HPF, high-power field (  400).
pFGFE+, intradermal injection of plasmid FGF-2 followed by
electroporation; pFGFE, intradermal injection of plasmid FGF-2;
pVAXE+, intradermal injection of vector backbone followed by
electroporation; PE, no treatment.

has been successfully used to increase the uptake and
expression of naked plasmid DNA in the skin and other
target tissues. The skin is an attractive target for the
Gene Therapy
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delivery of plasmid DNA because it allows for enhanced
control over expression levels and aids in targeting
expression to specific tissue areas. Further, if higher
expression levels are needed, the area treated or number
of treatments can be increased. Plasmid DNA has been
successfully delivered to the skin with in vivo EP for both
systemic and tissue-specific expression.19–22 This approach has shown promise in several fields including
vaccines22–26 and wound healing.27–30
The design of the electrode used for plasmid delivery
in this study, multielectrode array,11 allows for this
potential treatment for limb ischemia to be readily
translated to a clinical setting. One drawback of other
electrode designs is delivery of plasmid DNA to a large
surface area requires the distance between the electrode
pairs to be increased thereby the applied voltage must
also be increased for cell permeabilization to be effective.
The design of the multielectrode array allows for its
dimensions to be expanded by incorporating a larger
number of electrode pairs thus enabling a larger surface
area to be treated without the need to increase the
distance between electrodes.
In addition to direct injection of naked plasmid DNA,
the most prevalent methods of therapeutic administration of FGF-2 in the literature are viral-mediated
gene transfer and recombinant protein delivery. These
methods are promising for treatment of PAD but have
drawbacks. In human clinical trials, viral vectors have
caused inflammatory responses, formation of antibodies
to the viruses, transient fever31 and hepatotoxicity.32
Also, relative to nonviral gene transfer approaches, viralmediated delivery results in long-term and high levels
of gene expression increasing the potential for the
occurrence of the adverse side effects associated with
high levels of FGF-2 expression, such as toxicity and
proteinuria.6,33 In both animal models34–36 and clinical
trials,37–39 intramuscular injection or intra-arterial administration of recombinant FGF-2 protein improved PADrelated symptoms and or blood flow to the ischemia
limb, but the use of recombinant protein in a clinical
setting is often not practical due to its short half-life,37,40
poor bioavailability and consequently frequent administration is often required to sustain lasting effects. The
strategy developed here to deliver FGF-2 to an ischemic
limb is an attractive alternative to viral and recombinant
protein approaches because it allows for control of
localized expression level and duration. Also, pFGFE+
circumvents the possibility of adverse side effects and
practicality issues associated with viral and recombinant
protein delivery approaches.
Other studies have shown that intramuscular injection
of plasmid FGF-2 alone11 or followed by intramuscular
EP13,14 can improve ischemic hindlimb blood flow and
increase angiogenesis. Here, we have presented a simple,
noninvasive approach for delivery of pFGF with EP that
effectively increases FGF-2 protein expression, ischemic
limb blood flow and angiogenesis. The increased blood
flow and angiogenesis with pFGFE+ treatment may be
occurring through several known in vivo mechanisms.
FGF-2 is normally confined to the cell compartment but
is exported from the cell during active angiogenesis to
exert downstream effects.41 Thus, although pFGFE+
treatment is administered to the skin, increased levels
of FGF-2 protein after treatment and subsequent export
could activate downstream angiogenic pathways. For
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example, a recent study by Fujii et al.12 showed that in a
model of hindlimb ischemia, intramuscular injection of a
pFGF increased the expression of placental growth factor
through the upregulation of vascular endothelial growth
factor expression. Placental growth factor alone is known
to increase angiogenesis in models of hindlimb ischemia,
and it is possible a similar mechanism may be occurring
with pFGFE+.42,43 Another possible mechanism for the
increase in angiogenesis and hindlimb blood flow with
pFGFE+ treatment is the upregulation of hepatocyte
growth factor. FGF-2 stimulates hepatocyte growth factor
expression, which itself has also been successful in
increasing perfusion in hindlimb ischemia models.44,45
Further studies to characterize the exact mechanism of
pFGFE+ mediated angiogenesis are currently underway.
In summary, pFGFE+ treatment significantly increased
FGF-2 expression for 10 days after delivery and this
increase was sufficient to significantly increase blood
flow and angiogenesis in a rat model of hindlimb
ischemia. Translation of this therapeutic approach to
an appropriate large animal model, and eventually to
the clinic, will be the focus of future studies. Overall,
EP-mediated intradermal delivery of plasmid FGF-2 is
a potential noninvasive, nonviral therapeutic approach
to increase perfusion and angiogenesis in ischemic
limbs and warrants further investigation as a possible
treatment for PAD.

Materials and methods
Experimental animals
All procedures were approved by the Animal Use and
Care Committee of the University of South Florida
College of Medicine. A total of 34 male Sprague–Dawley
rats (275–300 g) were used in this study; 10 rats were
use to evaluate FGF-2 expression kinetics and 24 rats
were used for analysis of perfusion and capillary density.
Operations were performed using standard aseptic
techniques. Before all procedures, animals were anesthetized with 2.5–3.0% isoflurane in oxygen.
Hindlimb ischemia model
Hindlimb ischemia was induced in the right hindlimb of
the Sprague–Dawley rats. Through an approximately
2-cm-long incision parallel to the inguinal ligament, the
saphenous artery was ligated distally of the bifurcation
of the femoral artery into the saphenous and popliteal
arteries. The most distal end of the external iliac was
ligated immediately adjacent to the inguinal ligament
and the femoral artery was ligated proximal and distal to
the bifurcation of the superficial epigastric artery and
vein. The superficial epigastric artery and vein were also
ligated at two sites adjacent to the femoral bifurcation
and cut between these sites. The femoral artery was then
cut between the ligations adjacent to the inguinal
ligament and distally of the superficial epigastric artery
and vein. The femoral artery was then dissected free
from the point of the distal ligation of the saphenous
artery to the ligation of the femoral placed distally to the
bifurcation of the superficial artery and vein.
FGF-2 plasmid construction
The CMV promoter was removed from the pVAX1
plasmid (Invitrogen, Carlsbad, CA, USA) to create a
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promoterless pVAX1. The human FGF-2 plasmid (pFGF)
was cloned by subcloning the hEF1-IF4g-hbFGF sequence from pBLAST45-hbFGF2 (Invivogen, San Diego,
CA, USA) into the promoterless backbone of pVAX1.
Where indicated, vector backbone controls are the
pVAX1 backbone containing the hEF1-IF4g promoter.

Electroporation
After the operation to induce hindlimb, we randomized
ischemia animals into one of four treatment groups:
injection of pFGF with EP (pFGFE+), injection of pFGF
without EP (pFGFE), injection of vector backbone
with EP (pVAXE+) and no treatment (PE). All
injections were performed using a 25-gauge, 5/8-inchlength needle. Animals received two 50 ml intradermal
injections of plasmid DNA (2 mg ml1) in sterile injectable saline. The multielectrode array 11 was then placed
over the injection bubble and 150 ms pulses applied at a
field strength of 300 V cm1 (delivery to skin of rat flank
for initial expression kinetics) or 250 V cm1 (delivery to
the hindlimb). FGF-2 expression levels resulting from
pFGFE+ and pFGFE treatments were equivalent at
300 V cm1 when delivered to skin on flank of a rat and
250 V cm1 for delivery to the skin of the hindlimb and
did not differ between ischemic and nonischemic limbs
(data not shown).
FGF-2 protein expression
FGF-2 protein expression was determined by
enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN, USA). At the indicated time points,
the delivery sites were excised and snap frozen on dry
ice. Tissue samples were homogenized in 1–2 ml of lysis
buffer (150 mmol l1 NaCl, 20 mmol l1 sodium phosphate (pH 7.4), 10% glycerol, 1% NP-40 and protease
inhibitors (Roche, Indianapolis, IN, USA)). Homogenates
were then centrifuged at 4 1C for 10 min at 10 000 r.p.m.
The supernatants were removed and assayed for FGF-2
expression according to manufacturer’s instructions.
Measurement of blood flow by laser Doppler perfusion
imaging
A laser Doppler perfusion imager (Moor Instruments
Ltd., Devon, UK) was used to measure hindlimb blood
flow. Before measuring perfusion, we anesthetized and
placed animals on a warming pad to ensure constant
body temperature. A low-intensity (2 mW) laser light
beam (l ¼ 632.8 nm) scanned the surface of the skin
without contact at a standardized working distance of
25 cm. Scan modus was set at 10 ms per pixel and
resolution at 256  256 pixels. Three scans were completed per time point for each animal for both the
ischemic and nonischemic limbs and average perfusion
in arbitrary units (flux) was determined separately for
each limb. Perfusion in the ischemic limb was normalized to the contralateral nonischemic limb (I/NI) to
minimize variation due to ambient light and temperature. Baseline perfusion was assessed immediately
preoperatively and postoperative perfusion assessed
immediately after surgery but before treatment. The
I/NI was used to calculate percentage of baseline
perfusion at the postoperative time points.
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Immunohistochemistry
Two weeks after treatment, animals were killed and
tissue samples from the gastrocnemius muscle were
excised and fixed in 10% neutral buffered formalin for at
least 12 h at room temperature before embedding in
paraffin and sectioning (4 mm). Capillaries in the cross
sections were visualized using the Blood Vessel Staining
Kit (Millipore, Billerica, MA, USA) according to manufacturer’s instructions for factor VIII with hematoxylin
counterstaining. The number of factor VIII-positive
vessels was manually counted in a blinded manner in
five randomly selected fields (  400) for five animals
from each treatment group. The stained sections were
analyzed using a standard light microscope (Olympus
BX51; Olympus, Center Valley, PA, USA). The average
capillary density per high-power field (  400) for each
treatment group is reported. Representative fields from
each treatment group were photographed at  400 with
a Spot Insight 2 digital camera (Diagnostic Instruments,
Sterling Heights, MI, USA).
Statistical analysis
All values are reported as the mean±s.e.m. unless
otherwise noted. Analysis of FGF-2 expression and
capillary density was completed using a two-tailed
Student’s t-test. Analysis of blood flow was completed
by analysis of variance with post hoc Fisher’s least
significant difference to adjust for multiple group
comparisons. A post hoc Bonferroni correction was used
to adjust for multiple comparisons to pFGFE+ for
analysis of capillary density. All statistical analyses were
completed using the Statistical Package for the Social
Sciences (SPSS, Chicago, IL, USA).
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